Business News • PR NewsWire • ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study

ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study

ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study

BREDA, The Netherlands and GHENT, Belgium, December 17, 2013 /PRNewswire/ -- Dose confirmed for Phase Ib safety and efficacy expansion study arGEN-X announces that the dose-escalation part of a Phase Ib study with its lead antibody ARGX-110 has met its translational development goals:...

View More : http://www.prnewswire.com/news-releases/argx-110-a-novel-anti-cd70-antibody-meets-translational-development-goals-in-dos...

Releted News by prnewswire

51job, Inc. Announces Results of Annual Shareholders Meeting

Local Viewpoints Rebrands As ModernComment

Spriza, Inc. Launches Online Contest Marketing System - SPRIZA™

Global Machine Vision Systems & Components Market Report 2013-2018